# Merck KGaA to expand biologics site in Aubonne, Switzerland

Merck KGaA will invest €150 million to expand its biologics manufacturing site in Aubonne, Switzerland, adding a third building with aseptic filling lines and quality control labs. Construction is expected to be completed in 2020, with new lines operational by 2023.

- Type: Expansion
- Announced: 2019-03-28
- Where: Aubonne, Switzerland, Switzerland
- Value: $168.0M (150.0M EUR)
- Starts operating: 2023
- Status: announced
- Capacity: 27 million vials per year
- Products: biotech medicines, Gonal-f, Bavencio, M7824
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Merck KGaA](https://endata.com/companies/1393.md)

## Sources

- [genengnews.com](https://www.genengnews.com/news/merck-kgaa-to-expand-aubonne-switzerland-manufacturing-site/), 2019-03-28: "This investment reflects our commitment to ensuring that our medicines always meet the highest quality standards and are readily available to patients all over the world."
- [bioprocessintl.com](https://www.bioprocessintl.com/facilities-capacity/merck-to-up-drug-product-capacity-by-50-at-swiss-site), 2019-04-02: "The €150 million investment will cover a new building with two new lines for the aseptic filling – one for freeze-dried formulations, one for liquid formulations – of biological drugs, along with additional quality control labs."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.